Cullinan Therapeutics Inc (NASDAQ: CGEM) kicked off on Friday, up 3.77% from the previous trading day, before settling in for the closing price of $7.03. Over the past 52 weeks, CGEM has traded in a range of $6.85-$19.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -45.66% over the past five years. While this was happening, its average annual earnings per share was recorded -30.86%. With a float of $36.17 million, this company’s outstanding shares have now reached $59.07 million.
Let’s look at the performance matrix of the company that is accounted for 111 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cullinan Therapeutics Inc is 38.77%, while institutional ownership is 73.95%. The most recent insider transaction that took place on Feb 25 ’25, was worth 41,754. In this transaction Chief Medical Officer of this company sold 4,895 shares at a rate of $8.53, taking the stock ownership to the 174,164 shares. Before that another transaction happened on Feb 25 ’25, when Company’s President and CEO sold 12,529 for $8.53, making the entire transaction worth $106,872. This insider now owns 430,621 shares in total.
Cullinan Therapeutics Inc (CGEM) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.69 earnings per share (EPS), higher than consensus estimate (set at -0.77) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.89% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Take a look at Cullinan Therapeutics Inc’s (CGEM) current performance indicators. Last quarter, stock had a quick ratio of 9.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.52, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach -3.41 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 0.35 million, a negative change from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 20.78%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 17.73%, which indicates a significant decrease from 22.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.43 in the past 14 days, which was lower than the 0.46 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.08, while its 200-day Moving Average is $9.91. Nevertheless, the first resistance level for the watch stands at $7.61 in the near term. At $7.93, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.29. If the price goes on to break the first support level at $6.93, it is likely to go to the next support level at $6.57. The third support level lies at $6.25 if the price breaches the second support level.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
The company with the Market Capitalisation of 430.95 million has total of 59,015K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -167,380 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -48,500 K.
